AZD1705
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 24, 2026
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
(clinicaltrials.gov)
- P1 | N=96 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Dec 2025 ➔ Aug 2026 | Trial primary completion date: Dec 2025 ➔ Aug 2026
Trial completion date • Trial primary completion date • Cardiovascular • Dyslipidemia • Metabolic Disorders • APOB
May 20, 2025
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
(clinicaltrials.gov)
- P1 | N=96 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting
Enrollment closed • Cardiovascular • Dyslipidemia • Metabolic Disorders • APOB
February 02, 2024
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
(clinicaltrials.gov)
- P1 | N=112 | Recruiting | Sponsor: AstraZeneca
New P1 trial • Cardiovascular • Dyslipidemia • Metabolic Disorders
January 22, 2024
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
(clinicaltrials.gov)
- P1 | N=112 | Not yet recruiting | Sponsor: AstraZeneca
New P1 trial • Cardiovascular • Dyslipidemia • Metabolic Disorders
1 to 4
Of
4
Go to page
1